TRIPHED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIPHED (TRIPHED).
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating symptoms of allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing edema.
| Metabolism | Triprolidine undergoes hepatic metabolism via CYP450 enzymes. Pseudoephedrine is partially metabolized in the liver by N-demethylation; both are primarily excreted renally. |
| Excretion | Renal excretion of unchanged drug and metabolites accounting for approximately 60-70% of elimination; biliary/fecal elimination accounts for 20-30%. |
| Half-life | Terminal elimination half-life is 6-8 hours in adults with normal renal function; clinically, dosing interval adjustments are recommended in renal impairment. |
| Protein binding | 80-85% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution; clinically, loading doses may be required for rapid effect. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; Intramuscular: 80-90%; Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 10-15 minutes; Intravenous: 1-2 minutes. |
| Duration of Action | Oral: 4-6 hours; Parenteral: 3-5 hours; clinical effect may persist longer in hepatic impairment. |
Adults: Triprolidine 2.5 mg / pseudoephedrine 60 mg orally every 4-6 hours, not to exceed 4 doses in 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: extend dosing interval to every 8-12 hours; GFR <30 mL/min: not recommended, avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: use with caution, consider reducing dose or extending interval; Class C: contraindicated. |
| Pediatric use | Children 6-12 years: triprolidine 1.25 mg / pseudoephedrine 30 mg orally every 4-6 hours, max 4 doses/day; under 6 years: not recommended. |
| Geriatric use | Start with lower dose (e.g., half of adult dose) due to increased anticholinergic sensitivity and risk of urinary retention, dizziness, and hypertension; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIPHED (TRIPHED).
| Breastfeeding | Excreted in breast milk; M/P ratio unknown. Likely present in low concentrations. Monitor infant for drowsiness, poor feeding, and respiratory depression. Use only if essential and consider alternative agents. |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects, cardiac anomalies, and cleft palate based on animal studies and limited human data. Second and third trimesters: Potential for low birth weight, preterm delivery, and neonatal adaptation syndrome (hypotonia, respiratory depression). Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
No FDA Black Box Warning.
| Serious Effects |
["Hypersensitivity to triprolidine, pseudoephedrine, or any component","Severe hypertension or coronary artery disease","Concurrent or recent MAO inhibitor therapy","Narrow-angle glaucoma","Urinary retention","Breastfeeding (avoid due to pseudoephedrine)"]
| Precautions | ["Use caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, or prostatic hyperplasia due to pseudoephedrine component.","May cause drowsiness; avoid driving or operating machinery.","Avoid concurrent use with MAO inhibitors or within 14 days of discontinuation."] |
Loading safety data…
| Fetal Monitoring |
| Maternal: Blood pressure, heart rate, respiratory status, and signs of CNS depression. Fetal: Heart rate monitoring (non-stress test), ultrasonography for growth and anatomy, and biophysical profile if used in third trimester. |
| Fertility Effects | May cause menstrual irregularities, anovulation, and reduced fertility due to central nervous system depression and potential hormonal disruption. Discontinue to restore fertility. |